GlaxoSmithKline

GSK expands coronavirus antibody tie-up to include potential flu therapies

  • by

GlaxoSmithKline is expanding a coronavirus antibody collaboration with US biotech Vir, to include potential therapies for flu and other respiratory viruses. The big UK pharma is already working with Vir on antibody therapies for coronaviruses, and already have the antibody VIR-7831 in clinical trials including… Read More »GSK expands coronavirus antibody tie-up to include potential flu therapies

Britain could be mass-producing its Covid shot. Shame we junked our industrial base | Aditya Chakrabortty

  • by

The dire state of UK manufacturing has left us dependent on other nations. We may soon find out why some call this a ‘national security risk’ Everything now hinges on a vaccine: how many more Britons die, whether the NHS finally breaks, how long the… Read More »Britain could be mass-producing its Covid shot. Shame we junked our industrial base | Aditya Chakrabortty

GSK and Vir expand COVID-19 antibody trial after Trump’s treatment with Regeneron’s rival

  • by

GlaxoSmithKline and partner Vir Biotechnology are to expand a trial of an experimental antibody to treat COVID-19, putting heat on Regeneron’s rival that has been famously used to treat president Donald Trump. GSK and Vir began trials of the antibody on early-stage COVID-19 patients in… Read More »GSK and Vir expand COVID-19 antibody trial after Trump’s treatment with Regeneron’s rival

GSK nabs FDA approval for first-in-class multiple myeloma drug

  • by

Blenrep, an antibody-drug conjugate, is the first drug approved for multiple myeloma that targets the antigen BCMA. Several other companies are also developing BCMA-targeting therapies for the blood cancer, including CAR-T cells and bispecific antibodies.

GlaxoSmithKline makes bold move with £130m Covid-19 investment | Nils Pratley

  • by

GSK’s share price has been left standing by AstraZeneca’s high-risk success in cancer treatments Monday’s most important vaccine news was the promising early data from the Oxford University and AstraZeneca coronavirus trial – “robust immune responses” is encouraging. But let’s not overlook other vaccine developments.… Read More »GlaxoSmithKline makes bold move with £130m Covid-19 investment | Nils Pratley